Viewing Study NCT05113251


Ignite Creation Date: 2025-12-24 @ 11:47 PM
Ignite Modification Date: 2025-12-31 @ 4:36 PM
Study NCT ID: NCT05113251
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-11-18
First Post: 2021-10-22
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module